No matter how hard one tries to keep experimental conditions constant, inherent random fluctuations will inevitably cause variability between measurement results. This variability is a measure of the imprecision of the analytical method and, therefore, improvement of chemical analytical methods has been almost synonymous with improving the precision.
Systematic effects may also influence the result of measurement, causing poor accuracy of the result of measurement. The inaccuracy may be evaluated from measurements on certified reference materials or from participation in interlaboratory comparison studies. Documentation of accuracy is more demanding than documentation of precision, as the supply of both certified reference materials and interlaboratory comparison schemes is limited. Fortunately, the numbers of both are increasing steadily and now provide opportunity to document accuracy for an impressive number of parameters.
If precision and accuracy represent the traditional view on how to judge the reliability of measurement results, a change in paradigm is currently taking place in analytical chemistry. Precision and accuracy are being overshadowed by two new concepts, namely uncertainty and traceability. They are two faces of the same coin, as it is impossible to talk about traceability without referring to uncertainty, and vice versa. We would like to discuss these concepts in Traceability means that a result of measurement may be traced back, through an unbroken chain of comparisons, to a national or international standard.' To take an example, results expressed in mass base units of the International System of Units (SI), i.e. kg or multiples of kg, are traceable to the SI kg mass standard, which is defined by the kilogram standard kept by the Bureau International de Poids et Mesures (BIPM). Results in arbitrary units, e.g. World Health Organization (WHO) International Units (IU), are traceable to the standard, e.g. a WHO International Standard, that defines this unit.2 Each step in the comparison chain involves a measurement procedure, which contributes some uncertainty. Thus, the uncertainty is a quantitative measure of the strength of the traceability chain. As the uncertainty combines the uncertainty from all steps of the traceability chain, it gives information about the closeness of the result to the true value. (This definition appears in International Organization for Standards standard 3534. 3 We will not go into a discussion here, if 'a true value' would be a better wording than 'the true value'. It is more important to understand the difference between uncertainty and precision. Appendix A. 1 gives a more formal definition of uncertainty.) This is in contrast to precision which is a measure of the laboratory's ability to reproduce the measurement under some stated conditions.
At present, the concepts of traceability and uncertainty are more firmly rooted in physical measurements than in chemical a n a l y~e s .~ An example is weighing, where the traceability to the (SI) kilogram mass standard is managed by calibration with certified weights, which themselves are calibrated against weights placed higher in the metrological system and so on, ending with the international standard for the (SI) kilogram base unit. But the concepts of traceability and uncertainty are slowly moving into the field of analytical chemistry.
THE BIPM APPROACH TO UNCERTAINTY
Principles for estimating uncertainty have been recommended by the BIPM.' In 1993, the Guide to the Expression of Uncertainty in Measurement4 (referred to as the GUM) was published by the IS0 in the name of several eminent organizations with an interest in the field of metrology, among them the International Union for Pure and Applied Chemistry (IUPAC) and the International Federation of Clinical Chemistry (IFCC). The method of evaluating and expressing uncertainty in the GUM follows the BIPM approach.
Uncertainty (of a measurement result) can be defined as a parameter that quantitates our doubt about the exactness of the result (see Appendix A.l for a more formal definition of uncertainty). It may be expressed as a standard deviation, the halfwidth of a confidence interval, or a range which is believed to encompass a large fraction of the distribution of measurement results with a high probability. A standard uncertainty denotes an uncertainty which is expressed as a standard deviation. For example, the halfwidth of a confidence interval can be converted to the corresponding standard uncertainty by dividing with Student's t for the appropriate number of degrees of freedom (very often the t-value will be close to 2.0) (see Appendix A.2).
A basic premise of the concept described in the GUM is that uncertainty is composed of contributions from many different sources, uncertainty components. All uncertainty components should be evaluated and assigned a standard uncertainty. Uncertainty components are classified according to the method of evaluation: type A describes a standard uncertainty evaluated by statistical analysis of series of observations, and type B describes those uncertainty components that are evaluated by other means.4 These 'other means' may be evaluation from literature data, from a manual, from data obtained by other assays, or judged by an e~p e r t~,~ (see Appendix A.2 for more details of how to evaluate a type B uncertainty component).
The use of type B uncertainty components often causes controversy because the evaluation is not based on rigorous statistics, but on collateral information. True enough, the information used to estimate a type B component may differ in quality, ranging from experimental data on closely similar systems to 'educated guessing'. The G U M states that ' . . . proper use of the pool of available information for a Type B evaluation of standard uncertainty calls for insight based on experience and general knowledge, and is a skill that can be learned with practice'. It is therefore difficult to give general advice on how to treat type B components. However, it should be kept in mind that a type B uncertainty is not necessarily less reliable than type A uncertainties, especially not if the evaluation of type A uncertainty is based on a small number of data. Nevertheless, if type B uncertainties contribute heavily to the uncertainty of the measurement result, it would be prudent to obtain further information on these components.
The standard uncertainty of the measurement result is obtained by combining the standard uncertainties of the components according to the rules of combining variances (see Appendix A.3 for a more detailed description of how to combine uncertainties). The interval defined by the measurement result f standard uncertainty is expected to encompass only about 68% of the distribution of the measurement results. In order for the uncertainty to define an interval that encompasses a larger fraction of the distribution, the GUM recommends that the combined standard uncertainty is multiplied with a socalled coverage factor, usually with a value between 2 and 3. A coverage factor of 2 corresponds to a level of confidence of approximately 0.95, while a coverage factor of 3 corresponds to a level of confidence of approximately 0.99. The standard uncertainty multiplied by the coverage factor is called the expanded uncertainty. Whenever uncertainty is reported, the coverage factor should be stated.
Based on the GUM, Eurachem (European Analytical Chemists) have issued a guideline specific for analytical chemistry. 
APPLICATION TO CLINICAL BIOCHEMISTRY
The number of documents, standards and guidelines in preparation or already published, gives reason to suppose that traceability and uncertainty in the future will be standard requirements in the documentation of clinical chemistry measurement results. However, the application of these concepts in clinical chemistry is not straightforward. In order to open the debate and take a closer look at some of the obstacles, we have investigated the uncertainty components of a commercial radioimmunoassay (RIA), taking the determination of prolactin in serum as an example. With this assay as the starting point, we will discuss some aspects of uncertainty in protein hormone immunoassays.
Immunoassays, including RIA, are based on the interaction between antibodies and antigens. Although understood in principle, the actual mechanism of interaction is almost always unknown. Results produced by different assays are often not comparable. Nevertheless, ways have been found to make these assays work and produce useful results. Many practices have been introduced to minimize the comparability problem; for example results in proficiency testing schemes are grouped according to method and reference ranges are produced for each method, etc. There is also a drive to standardize assays with the aim of improving comparability, as discussed in a recent Personal View article in this Journal.'* Applying this uncertainty procedure to an immunoassay is not an easy task. The result of measurement and, hence, the uncertainty of the result, depends on several parameters, for example, the slope of the calibration curve, the signal measured on the sample (peak area, radioactive counts, absorbance, etc.), blank signal, corrections and correction factors, etc. The values of these parameters serve as input quantities in the model of the measurement, i.e. the mathematical relationship between the result of measurement and the p a r~m e t e r s .~ Establishing the mathematical model is necessary for RIA because of the complex relationship between the input quantities and the measurement result. The relationship is very often less complex for other analytical methods, and the correct way of combining uncertainty components may be recognized intuitively for such methods (see Appendix A.3).
Another problem is the assignment of values to suspected large uncertainty components, typically unknown systematic effects. Hopefully, future guidance documents for specific analytical chemistry fields, and more examples of uncertainty evaluations, will help to overcome these problems.
In this paper, we will not go into details of how to set up a mathematical model for a competitive RIA, or how to evaluate and combine standard uncertainties of RIA (examples of sources of uncertainty in RIA are shown in Table I ). A full description of the process would be very technical and beyond the remit of this article. Our aim is to introduce the principles of evaluating uncertainty and to discuss the problems related to the field of analytical chemistry. In the following sections we will focus on uncertainty components in calibration, and on uncertainty components that affect the sensitivity and specificity of the method.
Uncertainty of the calibrator concentrations
Most chemical analytical methods rely on calibration. As the concentration units are provided through calibration, the calibration procedure is an essential link in the traceability chain. In view of the pivotal role of the calibrators, it is an issue of great importance that all reagents of commercial kits are supplied by the manufacturer, including the calibrators. When trying to evaluate the uncertainty associated with calibration in prolactin measurements, we noted that the prolactin calibrators were stated in mass concentration units but-to our surprise-without uncertainty and without further information that could be used to judge the reliability of their values. In addition, a conversion factor for mass concentration unit to the International Units of the Third International Standard for prolactin (WHO IS 84/500)13 was given but, again, no information on calibration against the IS was provided. Unfortunately, this seems to be typical of commercial immunoassays.
Data obtained from the manufacturer on the calibration of the calibrators against WHO IS 84j500 were sufficient to produce estimates of the uncertainty of both the assigned mass concentration values and the conversion factor to IUs. The combined uncertainty of calibration was in the range of 25-30%0. The major contribution to uncertainty of calibration seemed to be uncertainty of the exactness of the calibrator values.
Combining the uncertainty of calibration with all other components of uncertainty resulted in a relative standard uncertainty of measurement results of approximately 30%, most of it coming from the uncertainty of calibration. (It is difficult to describe the actual combination of uncertainty components in a limited space due to the complex measurement model for a RIA. A paper describing the evaluation of uncertainty components and their combination for the prolactin RIA is in preparation by the authors.) The uncertainty should be compared to the inter-assay imprecision, which typically yields a coefficient of variation (CV) less than 10% (according to the manual). Therefore, comparison of different prolactin assays using imprecision estimates may lead to the conclusion, that they are 'not comparable', while a comparison based on uncertainty estimates demonstrates that the results indeed are comparable. The power of the uncertainty concept is that it is able to uncover the sources of discrepancy between assays. In our example, approximately 90% of the uncertainty of the prolactin result obtained by our kit was due to uncertainty of the calibrator values. Although one cannot generalize from one assay, this conclusion underlines the need for standardized procedures for establishing and documenting the accuracy and traceability of the assigned values of the calibrators.
The uncertainty of the 'correct result' With protein hormone immunoassays it seems to be the opinion that the 'correct' result does not exist because the molecular heterogeneity of the analytes and the different potency of individual molecular species in any given assay make it impossible to define the 'correct' results.'* Three components of uncertainty are contributing to these circumstances: (1) uncertainty from the definition of the entity to be quantified; (2) uncertainty from specificity problems of the measurement method; and (3) uncertainty from sensitivity problems of the measurement method.
The definition of the entity to be quantified may contribute to the uncertainty of the result of m e a~u r e m e n t .~,~ In the prolactin example, the entity to be quantified is the concentration of prolactin in human serum. However, this simple definition is beset with uncertainty. Specifically, prolactin is normally present as monomers (molecular mass around 22 800), but sometimes dimers and trimers are observed. 1 4 3 1 5 Should these forms be called prolactin? If there is reasonable doubt about this, then the existence of these forms constitutes an uncertainty component. In principle, if the prevalence of these forms can be judged, the uncertainty of the definition of the substance to be measured can be estimated. To take an example, patients with tumours in the pituitary gland sometimes produce large amounts of prolactin oligomers. 15 If we know, for example from experience or from the literature, that up to 50% of total prolactin in the serum of such patients may be oligomers, this constitutes a relative uncertainty of 50% when measuring prolactin in serum from such a patient. This uncertainty can be converted to a standard uncertainty by making assumptions about its distribution, as outlined in the Appendix. This uncertainty component reflects our doubt about the definition of the entity to be quantified. However, in our RIA example, prolactin is described in the manual accompanying the commercial kit as a polypeptide hormone with a molecular mass of about 22800. Thus, it would be reasonable to assume that the prolactin defined by the manual is the monomer form only.
This automatically leads to the next component of uncertainty: Is the method specific for prolactin monomers? The antibody in our assay may bind prolactin monomers only, or it may bind both monomers, dimers and trimers. Only in the first case are the measurements 'correct', because we assume that prolactin is defined as prolactin monomers. But 'foreign' molecules may also bind in the assay (cross-reactivity), or the antibody may fail to bind some isoforms of prolactin (in which case the assay is too specific). Such measurements cannot be said to be 'correct'.
The effect from interfering compounds may be both positive and negative. For example, the presence of prolactin dimers and trimers may lead to increased estimates of the prolactin monomers content, while the presence of haemoglobin (from haemolysis) in the serum may decrease the result. The effect may be estimated experimentally: for example, in our prolactin assay the manual reports the effect of haemolysis as simulated by measuring prolactin in samples with various amounts of packed red blood cells (0-3OpL per mL serum). With mild haemolysis the average recovery was 98.5% and with severe haemolysis was 66%. This illustrates the principle for obtaining estimates of systematic effects from interfering compounds. Of course, measurement results should be corrected for known systematic effect.I6 However, for many reasons the value of the correction cannot be known exactly: first, the estimation of the correction is subject to uncertainty, and second, the concentration of interfering molecules may not be constant but may vary between different samples depending on patient, time, clinical condition etc. Thus, the value of the correction must be established for a typical concentration of the interfering compound, and the uncertainty of the value estimated from reasonable minimum and maximum concentrations of the interfering species. Sound judgement must be exerted in evaluating these minimum and maximum concentrations; they should encompass natural intra-and interindividual variability as well as the effect of trivial (but frequently encountered) clinical conditions (e.g. a common cold, infections). Sometimes there is evidence of interference, but there is insufficient information to allow its effect on the measurement results to be evaluated. Although a correction factor of one (1) must be applied in such cases, it does not release one from the duty of estimating the uncertainty of the correction The last step in evaluating the uncertainty of the 'correct' result is to consider the sensitivity. By sensitivity we mean the change in analytical signal (which is the radioactivity in our example) divided by the change in concentration of the analyte. The problem is that different isoforms of prolactin may have different potency in the assay and may, therefore, give different results. In our competitive-type RIA this problem is caused by the different affinities between the primary antibody and the various molecular forms of prolactin. In other types of assays, sensitivity problems may also involve binding of a secondary antibody to various molecular forms of the analyte. In our example, the uncertainty from sensitivity problems can be estimated, in principle, from the variability of the affinity constants of the antibody to various forms of prolactin or, alternatively, one may use information from other antibody-antigen interactions to get an idea of the effect. Another way to judge the sensitivity would be to measure the analytical signal (radioactivity) for the same amount of various forms of prolactin. The variability in signals is the uncertainty component associated with differences in sensitivity. In practice, however, it is very difficult to carry out these experiments; pure preparations of the desired forms of the molecule in question are rarely available and, even if they were, it would be very difficult to establish the amount (i.e. the number of moles) of each molecular form with sufficient accuracy.
As mentioned, the uncertainties of the definition of the entity to be quantified, together with the uncertainty of the specificity and sensitivity, are relevant to the problem of getting the correct result. Obviously, from an uncertainty point of view, the 'correct' result can indeed be defined, but the definition is beset with uncertainty! The advantage of the uncertainty approach is that it exposes the causes of discrepancies, and therefore identifies targets for improvements. However, as the discussion above shows, there are still many problems in establishing standard
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DISCUSSION
The BIPM approach to uncertainty provides a framework for treating and quantifying uncertainty components, including those considered difficult and which have made it impossible to compare immunoassay results, e.g. molecular heterogeneity, definition of the entity to be quantified, quality of the antibody reagent, etc. We are convinced of the advantages of the uncertainty concept, but we acknowledge that several problems have to be solved before the full benefit of it can be obtained in the clinical chemistry field. Among the problems are documentation of reagents in kits, including the calibrator values and their uncertainty. Another problem is the type B evaluation of standard uncertainties. Some uncertainty components, for example matrix interferences, may occur sporadically due to some special circumstances (for example the condition of the patient), and others seem impossible to address with the present state of the art, as described in the previous section. How should one cope with such components? There are no easy answers to these questions, but one suggestion would be that the chemist should be prepared to include information from other systems in order to evaluate uncertainty components. He should also be ready to exert what the GUM terms 'sound judgement' in quantifying uncertainties. This may seem alien to the chemist who upholds the ideal of the scientific objectivity of measurement results. But one must recall that such less objective procedures are already in use in other scientific fields, e.g. in risk analysis of chemicals, which involves extrapolation between species and application of a variety of safety factors in the process.18 Maybe it is necessary to recognize that the doubt about the exactness of a measurement result (i.e. the uncertainty) cannot be quantified with the same scientific objectivity as the result itself. This situation may be acceptable, as long as it is maintained that the measurement result is the primary outcome of a measurement, and is more important than the associated uncertainty.
A different type of problem is the complexity of modelling the measurement procedure, which is necessary in order to describe the influence of various input quantities on the measurement result. In a time of increasing automation of analyses and calculations, the requirement of a detailed mathematical description of the measurement procedure seems to go against the tide. To overcome this obstacle, it may be necessary to skip detailed analyses of the measurement and focus on fewer, but important, uncertainty components, but which? Again, there are no easy answers. Based on our experience with the prolactin kit, as well as with other analytical methods (atomic absorption s p e~t r o m e t r y l~, '~ and high-performance liquid chromatography), we suggest it is always worthwhile to consider the uncertainty of calibration. The reason is that calibration is a key step in most analytical methods and an essential link in traceability. If calibration goes wrong, all results are wrong.
This leads us to comment on our specific example. The enormous uncertainty of a prolactin measurement (combined relative standard uncertainty 30%, or an expanded relative uncertainty of -t 60% using a coverage factor of 2) points to the need for documentation of traceability (and uncertainty) of calibrators in commercial clinical chemistry kits. In our opinion, it should rest with the manufacturers of such kits to provide adequate documentation of the exactness of the calibrator values in accordance with (coming) international standards and guidelines. '' While the large uncertainty involved in prolactin measurements in our example points to problems in the traceability chain, the information provided by a large uncertainty may not be very valuable in the treatment of an individual patient. Therefore, it will be necessary to rely on imprecision and in-house reference ranges until the uncertainty is reduced to a reasonable level. However, it may be valuable to communicate the uncertainty, even a large one, in connection with research results. We hope that in time, with the relevant legislation and standards in place, manufacturers will produce immunoassays of a much better metrological quality, and if this happens the uncertainty of immunoassay measurement results will eventually decrease.
However, progress does not depend solely on the manufacturers. Clinical chemists using the kits need to be familiar with the concepts of traceability and uncertainty. If not, the documentation provided with the commercial assays will be worthless, and the reliability of the measurement results cannot be properly communicated. Moreover, users of analytical results, e.g. medical doctors, must be critical of them Ann Clin Biocheni 1998: 35 and request proper documentation of their reliability. They must also be able to understand the meaning of an uncertainty statement. To obtain such a high state of awareness of measurement and measurement problems requires that responsible organizations on all levels train and educate their members to use and understand the concepts of uncertainty and traceability." We believe that these concepts should be adopted in a gradual manner, allowing time for a dialogue between relevant parties (legislators, analytical chemists, users of measurement results, etc.), and taking into account the state of the art of the field.
Traceability and uncertainty are indispensable concepts in metrology. A field using and relying on measurements is not sound in a metrological sense without traceability and uncertainty. It is our belief, and wish, that, in time, the concepts of traceability and uncertainty will be firmly established in the analytical chemistry field. This will be a great step towards bringing analytical chemistry onto a more sound metrological basis.
APPENDIX

A.l Definition of uncertainty
The formal definition of the term 'uncertainty of measurement' is as follows.' Uncertainty (of measurement) Parameter, associated with the result of a measurement, that characterized the dispersion of the values that could reasonably be attributed to the medsurand
Notes
The parameter may be, for example, a standard deviation, or the half-width of an interval having a stated level of confidence. Uncertainty comprises, in general, many components. Some of these components may be evaluated from the statistical evaluation of the results of series of measurements and can be characterized by experimental standard deviations. The other components, which also can be characterized by standard deviations, are evaluated from assumed probability distributions based on experience or other information. It is understood that the result of the measurement is the best estimate of the value of the measurand, and that all components of uncertainty, including those arising from systematic effects, such as components associated with corrections and reference standards, contribute to the dispersion.
In practice, there are many possible sources of uncertainty in a measurement, including:
Incomplete definition of the measurand (i.e. the quantity to be measured) Sample heterogeneity Inexact values of calibrators Matrix differences between sample and calibrators Stability of the sample, the analyte or reagents used in the measurement process The presence of interfering compounds in the sample (lack of specificity) Imprecision of statistical algorithms used on results on calibrators Random variability inherent in the measurement process
A.2 Type B evaluation of standard uncertainty
The combination of uncertainties (see Section A.3 below) requires that all contributions are converted to standard uncertainties. A standard uncertainty is easily obtained in a type A evaluation, because a standard deviation can be calculated directly.
When a direct statistical approach in evaluating a component of uncertainty is not possible, one must use all available information and knowledge to evaluate the uncertainty. It is not possible here, in limited space, to give an exhaustive introduction on how to do a type B evaluation. The principles are thoroughly described in the GUM, but it can only be learned by trying it in practice. The typical procedure of a type B evaluation is: (1) estimate some (reasonable) limits for the value an input quantity can take. The interval between these limits constitutes the uncertainty; (2) assume a (reasonable) distribution of the value of the input quantity within these limits; and (3) calculate the standard uncertainty from the uncertainty and the assumed distribution.
Examples of type B evaluations: ( I ) The value of certified reference material is accompanied by a statement of its uncertainty, stating that 'the uncertainty corresponds to the halfwidth of the 95% confidence interval'. If no further information is presented, one is allowed to assume a normal distribution. The standard uncertainty of the certified value can be estimated by dividing the stated uncertainty by 2 (as the mean two standard deviations covers approximately 95% of a normal distribution).
(2) Non-linearity of the calibration function for prolactin in serum determined by RIA. The calibration function is estimated by linear regression. No non-linearity effects are apparent from normal calibration graphs. The effect of non-linearity can be investigated by drawing curves with the maximal curvature allowed by the calibration points. The maximal change, Ax, in the value read from the abscissa (x) for a given value of y may be taken as the uncertainty from non-linearity. However, this is the maximal effect of non-linearity; in other words, the effect of non-linearity may take a value in the interval between -Ax and +Ax. All values in the interval are equally likely, while the probability of a value outside this interval is zero. Thus, the effect is described by a rectangular distribution with zero mean and half-width Ax. The standard deviation of this distribution is given by the halfwidth divided by J3. Therefore, the standard uncertainty of non-linearity is u = Ax/J3 (type B evaluation).
A.3 Evaluating standard uncertainty
In principle, the result of a measurement, y , depends on several input quantities, xi. A simple example, from atomic absorption spectrometry,I7 shows how the observed concentration is calculated from input quantities:
where A is the atomic absorption measured on the sample, A. is the atomic absorption of the blank sample, and b the slope of the calibration curve.
How can the standard uncertainty on C be evaluated from the standard uncertainties of A , A,, and b? The rule of combining variancesz0 states that for input quantities related only by summation or subtraction, the variance of the measurement result is equal to the sum of the variances of the input quantities, thus Furthermore, for input quantities related by multiplication or division, the relative variance of the measurement result is equal to the sum of the relative variances of the input quantities:
From equation (A.l) it is observed that the functional relationship between A , A. and b involves both subtraction and division. Applying the rules expressed by equation (A.2) and (A.3) in sequence, the following expression for the uncertainty of C is derived: Equation (A.4) describes how to calculate the uncertainty of C from the uncertainty of the signal (uA), the uncertainty of the blank signal (uA,,) and the uncertainty of the calibration slope (ub). Of course, these uncertainty components are themselves composed of several uncertainty components, which may be expressed by using the same procedure as just de~cribed.'~.~'
The simple rules of combining variances presented above do not reveal how to treat a more complex relation between the input quantities, or what to do in case of covariance between the values of input quantities. A more general applicable rule of combining variances20 is expressed by the equation (A.5) for the relation between input quantities described by the general function J': y = f ( x l r X * ,... x, )... &).
('4.6)
The reader should be aware that the critical step is establishing the functional relationship J' [in equation (A.6)], as accessible numerical methods for solving equation (A.5) are described in the literature.2'
